Skip to main content
Top
Published in: Medical Oncology 4/2012

01-12-2012 | Original Paper

Inhibition of silibinin on migration and adhesion capacity of human highly metastatic breast cancer cell line, MDA-MB-231, by evaluation of β1-integrin and downstream molecules, Cdc42, Raf-1 and D4GDI

Authors: Mohadeseh Dastpeyman, Nasrin Motamed, Kayhan Azadmanesh, Ehsan Mostafavi, Vahid Kia, Ali Jahanian-Najafabadi, Mohammad Ali Shokrgozar

Published in: Medical Oncology | Issue 4/2012

Login to get access

Abstract

Metastasis is a property of malignant cancer cells that requires integrins which with their downstream molecules participate in a number of signaling events in cells with pivotal roles in malignancy, migration and invasion of tumor cells. Silibinin, a flavonoid antioxidant from milk thistle (Silybum marianum L.), has attracted attention in the last decades for chemoprevention and chemotherapy of tumor cells. In the present study, the effect of silibinin on migration and adhesion capacity of MDA-MB-231 cells, a highly metastatic human breast cancer cell line, was investigated by evaluation of β1-integrin and its important downstream molecules. MTT, migration and adhesion assays were performed to evaluate the silibinin effects on proliferation, migration and adhesion of MDA-MB-231 cells. In addition, the influence of the silibinin on the expression of β1-integrin, Raf-1, Cdc42 and D4-GDI mRNAs was assessed by RT-PCR. Results showed significant dose-dependent inhibitory effect of silibinin on proliferation, migration and adhesion of MDA-MB-231 cells. It significantly inhibited the expression of Cdc42 and D4-GDI mRNAs but had no statistically significant effect on the expression of β1-integrin and Raf-1 mRNAs although it indirectly but effectively modulated β1-integrin signaling pathway and RAF1 function. In conclusion, the results showed the silibinin effectson reducing the rate of metastasis, migration and adhesion of MDA-MB-231 to distant organs.
Literature
1.
go back to reference Bernard-Marty C, Cardoso F, Piccart MJ. Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist. 2004;9(6):617–32.PubMedCrossRef Bernard-Marty C, Cardoso F, Piccart MJ. Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist. 2004;9(6):617–32.PubMedCrossRef
2.
go back to reference Raina K, Agarwal R. Combinatorial strategies for cancer eradication by silibinin and cytotoxic agents: efficacy and mechanisms1. Acta Pharmacol Sin. 2007;28(9):1466–75.PubMedCrossRef Raina K, Agarwal R. Combinatorial strategies for cancer eradication by silibinin and cytotoxic agents: efficacy and mechanisms1. Acta Pharmacol Sin. 2007;28(9):1466–75.PubMedCrossRef
3.
go back to reference Ramasamy K, Agarwal R. Multitargeted therapy of cancer by silymarin. Cancer Lett. 2008;269(2):352–62.PubMedCrossRef Ramasamy K, Agarwal R. Multitargeted therapy of cancer by silymarin. Cancer Lett. 2008;269(2):352–62.PubMedCrossRef
4.
go back to reference Mokhtari MJ, Motamed N, Shokrgozar MA. Evaluation of silibinin on the viability, migration and adhesion of the human prostate adenocarcinoma (PC-3) cell line. Cell Biol Int. 2008;32(8):888–92.PubMedCrossRef Mokhtari MJ, Motamed N, Shokrgozar MA. Evaluation of silibinin on the viability, migration and adhesion of the human prostate adenocarcinoma (PC-3) cell line. Cell Biol Int. 2008;32(8):888–92.PubMedCrossRef
5.
go back to reference Momeny M, Khorramizadeh MR, Ghaffari SH, Yousefi M, Yekaninejad MS, Esmaeili R, et al. Effects of silibinin on cell growth and invasive properties of a human hepatocellular carcinoma cell line, HepG-2, through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation. Eur J Pharmacol. 2008;591(1–3):13–20.PubMedCrossRef Momeny M, Khorramizadeh MR, Ghaffari SH, Yousefi M, Yekaninejad MS, Esmaeili R, et al. Effects of silibinin on cell growth and invasive properties of a human hepatocellular carcinoma cell line, HepG-2, through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation. Eur J Pharmacol. 2008;591(1–3):13–20.PubMedCrossRef
6.
go back to reference Wu K, Zeng J, Zhu G, Zhang L, Zhang D, Li L, et al. Silibinin inhibits prostate cancer invasion, motility and migration by suppressing vimentin and MMP-2 expression. Acta Pharmacol Sin. 2009;30:1162–8.PubMedCrossRef Wu K, Zeng J, Zhu G, Zhang L, Zhang D, Li L, et al. Silibinin inhibits prostate cancer invasion, motility and migration by suppressing vimentin and MMP-2 expression. Acta Pharmacol Sin. 2009;30:1162–8.PubMedCrossRef
7.
go back to reference Brandon-Warner E, Sugg JA, Schrum LW, McKillop IH. Silibinin inhibits ethanol metabolism and ethanol-dependent cell proliferation in an in vitro model of hepatocellular carcinoma. Cancer Lett. 2010;291(1):120–9.PubMedCrossRef Brandon-Warner E, Sugg JA, Schrum LW, McKillop IH. Silibinin inhibits ethanol metabolism and ethanol-dependent cell proliferation in an in vitro model of hepatocellular carcinoma. Cancer Lett. 2010;291(1):120–9.PubMedCrossRef
8.
go back to reference Chen PN, Hsieh YS, Chiou HL, Chu SC. Silibinin inhibits cell invasion through inactivation of both PI3 K-Akt and MAPK signaling pathways. Chem Biol Interact. 2005;156(2–3):141–50.PubMedCrossRef Chen PN, Hsieh YS, Chiou HL, Chu SC. Silibinin inhibits cell invasion through inactivation of both PI3 K-Akt and MAPK signaling pathways. Chem Biol Interact. 2005;156(2–3):141–50.PubMedCrossRef
9.
go back to reference Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2(2):91–100.PubMedCrossRef Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2(2):91–100.PubMedCrossRef
10.
go back to reference Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9–22.PubMedCrossRef Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9–22.PubMedCrossRef
11.
go back to reference Schlaepfer DD, Hauck CR, Sieg DJ. Signaling through focal adhesion kinase. Prog Biophys Mol Biol. 1999;71(3–4):435–78.PubMedCrossRef Schlaepfer DD, Hauck CR, Sieg DJ. Signaling through focal adhesion kinase. Prog Biophys Mol Biol. 1999;71(3–4):435–78.PubMedCrossRef
12.
go back to reference Machacek M, Hodgson L, Welch C, Elliott H, Pertz O, Nalbant P, et al. Coordination of Rho GTPase activities during cell protrusion. Nature. 2009;461(7260):99–103.PubMedCrossRef Machacek M, Hodgson L, Welch C, Elliott H, Pertz O, Nalbant P, et al. Coordination of Rho GTPase activities during cell protrusion. Nature. 2009;461(7260):99–103.PubMedCrossRef
13.
go back to reference Burbelo P, Wellstein A, Pestell RG. Altered Rho GTPase signaling pathways in breast cancer cells. Breast Cancer Res Treat. 2004;84(1):43–8.PubMedCrossRef Burbelo P, Wellstein A, Pestell RG. Altered Rho GTPase signaling pathways in breast cancer cells. Breast Cancer Res Treat. 2004;84(1):43–8.PubMedCrossRef
14.
go back to reference Dovas A, Couchman JR. RhoGDI: multiple functions in the regulation of Rho family GTPase activities. Biochem J. 2005;390(1):1–9.PubMedCrossRef Dovas A, Couchman JR. RhoGDI: multiple functions in the regulation of Rho family GTPase activities. Biochem J. 2005;390(1):1–9.PubMedCrossRef
15.
go back to reference Zhang Y, Zhang B. D4-GDI, a Rho GTPase regulator, promotes breast cancer cell invasiveness. Cancer Res. 2006;66(11):5592–8.PubMedCrossRef Zhang Y, Zhang B. D4-GDI, a Rho GTPase regulator, promotes breast cancer cell invasiveness. Cancer Res. 2006;66(11):5592–8.PubMedCrossRef
16.
go back to reference Kolch W, Kotwaliwale A, Vass K, Janosch P. The role of Raf kinases in malignant transformation. Expert Rev Mol Med. 2002;4(08):1–18.PubMedCrossRef Kolch W, Kotwaliwale A, Vass K, Janosch P. The role of Raf kinases in malignant transformation. Expert Rev Mol Med. 2002;4(08):1–18.PubMedCrossRef
17.
go back to reference Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther. 2005;4(4):677–85.PubMedCrossRef Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther. 2005;4(4):677–85.PubMedCrossRef
18.
go back to reference Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10(6):515–27.PubMedCrossRef Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10(6):515–27.PubMedCrossRef
19.
go back to reference Sharp JA, Waltham M, Williams ED, Henderson MA, Thompson EW. Transfection of MDA-MB-231 human breast carcinoma cells with bone sialoprotein (BSP) stimulates migration and invasion in vitro and growth of primary and secondary tumors in nude mice. Clin Exp Metastasis. 2004;21(1):19–29.PubMedCrossRef Sharp JA, Waltham M, Williams ED, Henderson MA, Thompson EW. Transfection of MDA-MB-231 human breast carcinoma cells with bone sialoprotein (BSP) stimulates migration and invasion in vitro and growth of primary and secondary tumors in nude mice. Clin Exp Metastasis. 2004;21(1):19–29.PubMedCrossRef
20.
21.
go back to reference Dhanesuan N, Sharp JA, Blick T, Price JT, Thompson EW. Doxycycline-inducible expression of SPARC/Osteonectin/BM40 in MDA-MB-231 human breast cancer cells results in growth inhibition. Breast Cancer Res Treat. 2002;75(1):73–85.PubMedCrossRef Dhanesuan N, Sharp JA, Blick T, Price JT, Thompson EW. Doxycycline-inducible expression of SPARC/Osteonectin/BM40 in MDA-MB-231 human breast cancer cells results in growth inhibition. Breast Cancer Res Treat. 2002;75(1):73–85.PubMedCrossRef
22.
go back to reference Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55(4):611–22.PubMedCrossRef Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55(4):611–22.PubMedCrossRef
23.
go back to reference Pfaffl MW. Quantification strategies in real-time PCR. In: Bustin SA La Jolla (ed) A–Z of quantitative PCR. USA: International University Line; 2004. pp 87–112. Pfaffl MW. Quantification strategies in real-time PCR. In: Bustin SA La Jolla (ed) A–Z of quantitative PCR. USA: International University Line; 2004. pp 87–112.
24.
go back to reference Radoni A, Thulke S, Mackay IM, Landt O, Siegert W, Nitsche A. Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun. 2004;313(4):856–62.CrossRef Radoni A, Thulke S, Mackay IM, Landt O, Siegert W, Nitsche A. Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun. 2004;313(4):856–62.CrossRef
25.
go back to reference Goodarzi A, Vousooghi N, Sedaghati M, Mokri A, Zarrindast MR. Dopamine receptors in human peripheral blood lymphocytes: changes in mRNA expression in opioid addiction. Eur J Pharmacol. 2009;615(1–3):218–22.PubMedCrossRef Goodarzi A, Vousooghi N, Sedaghati M, Mokri A, Zarrindast MR. Dopamine receptors in human peripheral blood lymphocytes: changes in mRNA expression in opioid addiction. Eur J Pharmacol. 2009;615(1–3):218–22.PubMedCrossRef
26.
go back to reference Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST (C)) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002;30(9):30–6.CrossRef Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST (C)) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002;30(9):30–6.CrossRef
27.
go back to reference Chen PN, Hsieh YS, Chiang CL, Chiou HL, Yang SF, Chu SC. Silibinin inhibits invasion of oral cancer cells by suppressing the MAPK pathway. J Dental Res. 2006;85(3):220–5.CrossRef Chen PN, Hsieh YS, Chiang CL, Chiou HL, Yang SF, Chu SC. Silibinin inhibits invasion of oral cancer cells by suppressing the MAPK pathway. J Dental Res. 2006;85(3):220–5.CrossRef
28.
go back to reference Yao ES, Zhang H, Chen YY, Lee B, Chew K, Moore D, et al. Increased 1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res. 2007;67(2):659–64.PubMedCrossRef Yao ES, Zhang H, Chen YY, Lee B, Chew K, Moore D, et al. Increased 1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res. 2007;67(2):659–64.PubMedCrossRef
29.
go back to reference Gassmann P, Haier J, Nicolson GL. Cell adhesion and invasion during secondary tumor formation: interactions between tumor cells and host organs. Selected Aspects of Cancer Progression: Metastasis, Apoptosis and Immune Response. 2008;11:21–32.CrossRef Gassmann P, Haier J, Nicolson GL. Cell adhesion and invasion during secondary tumor formation: interactions between tumor cells and host organs. Selected Aspects of Cancer Progression: Metastasis, Apoptosis and Immune Response. 2008;11:21–32.CrossRef
30.
go back to reference Keely PJ, Westwick JK, Whitehead IP, Der CJ, Parise LV. Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI (3) K. Nature. 1997;390(6660):632–6.PubMedCrossRef Keely PJ, Westwick JK, Whitehead IP, Der CJ, Parise LV. Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI (3) K. Nature. 1997;390(6660):632–6.PubMedCrossRef
31.
go back to reference Adelsman MA, McCarthy JB, Shimizu Y. Stimulation of beta1-integrin function by epidermal growth factor and heregulin-beta has distinct requirements for erbB2 but a similar dependence on phosphoinositide 3-OH kinase. Mol Biol Cell. 1999;10(9):2861–78.PubMed Adelsman MA, McCarthy JB, Shimizu Y. Stimulation of beta1-integrin function by epidermal growth factor and heregulin-beta has distinct requirements for erbB2 but a similar dependence on phosphoinositide 3-OH kinase. Mol Biol Cell. 1999;10(9):2861–78.PubMed
32.
go back to reference Bei Z, Li-jun WU, Shin-ichi Tashiro SO, Fumiaki Uchiumi TI. Activation of extracellular signal-regulated kinase during silibinin-protected, isoproterenol-induced apoptosis in rat cardiac myocytes is tyrosine kinase pathway-mediated and protein kinase C-dependent. Acta Pharmacol Sin. 2007;28(6):803–10.CrossRef Bei Z, Li-jun WU, Shin-ichi Tashiro SO, Fumiaki Uchiumi TI. Activation of extracellular signal-regulated kinase during silibinin-protected, isoproterenol-induced apoptosis in rat cardiac myocytes is tyrosine kinase pathway-mediated and protein kinase C-dependent. Acta Pharmacol Sin. 2007;28(6):803–10.CrossRef
33.
go back to reference Handorean AM, Yang K, Robbins EW, Flaig TW, Iczkowski KA. Silibinin suppresses CD44 expression in prostate cancer cells. Am J Transl Res. 2009;1(1):80–6.PubMed Handorean AM, Yang K, Robbins EW, Flaig TW, Iczkowski KA. Silibinin suppresses CD44 expression in prostate cancer cells. Am J Transl Res. 2009;1(1):80–6.PubMed
34.
go back to reference Mokhtari MJ, Shokrgozar MA, Motamed N, Akbarzadeh A, Moumeni M, Kamiab AR, et al. Up regulation of CD82 gene in prostat cancer PC-3 cell line treated with silibinin. Modares J Med Sci (Pathobiology). 2010;13(3):41–52. Mokhtari MJ, Shokrgozar MA, Motamed N, Akbarzadeh A, Moumeni M, Kamiab AR, et al. Up regulation of CD82 gene in prostat cancer PC-3 cell line treated with silibinin. Modares J Med Sci (Pathobiology). 2010;13(3):41–52.
35.
go back to reference Momeny M, Malehmir M, Zakidizaji M, Ghasemi R, Ghadimi H, Shokrgozar MA, et al. Silibinin inhibits invasive properties of human glioblastoma U87MG cells through suppression of cathepsin B and nuclear factor kappa B-mediated induction of matrix metalloproteinase 9. Anticancer Drugs. 2010;21(3):252–60.PubMedCrossRef Momeny M, Malehmir M, Zakidizaji M, Ghasemi R, Ghadimi H, Shokrgozar MA, et al. Silibinin inhibits invasive properties of human glioblastoma U87MG cells through suppression of cathepsin B and nuclear factor kappa B-mediated induction of matrix metalloproteinase 9. Anticancer Drugs. 2010;21(3):252–60.PubMedCrossRef
36.
37.
go back to reference Mokhtari MJ, Kamyab R. Up regulation of KAI1 and NM23 genes in prostate cancer DU145 and LNCaP cell lines treated by silibinin. Clin Biochem. 2011. 44(13):S203. Mokhtari MJ, Kamyab R. Up regulation of KAI1 and NM23 genes in prostate cancer DU145 and LNCaP cell lines treated by silibinin. Clin Biochem. 2011. 44(13):S203.
38.
go back to reference Morreale A, Venkatesan M, Mott HR, Owen D, Nietlispach D, Lowe PN, et al. Structure of Cdc42 bound to the GTPase binding domain of PAK. Nat Struct Mol Biol. 2000;7(5):384–8.CrossRef Morreale A, Venkatesan M, Mott HR, Owen D, Nietlispach D, Lowe PN, et al. Structure of Cdc42 bound to the GTPase binding domain of PAK. Nat Struct Mol Biol. 2000;7(5):384–8.CrossRef
Metadata
Title
Inhibition of silibinin on migration and adhesion capacity of human highly metastatic breast cancer cell line, MDA-MB-231, by evaluation of β1-integrin and downstream molecules, Cdc42, Raf-1 and D4GDI
Authors
Mohadeseh Dastpeyman
Nasrin Motamed
Kayhan Azadmanesh
Ehsan Mostafavi
Vahid Kia
Ali Jahanian-Najafabadi
Mohammad Ali Shokrgozar
Publication date
01-12-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-0113-8

Other articles of this Issue 4/2012

Medical Oncology 4/2012 Go to the issue